This week's dividend activity included increased payouts from General Mills (GIS) and Worthington Enterprises (WOR) as well ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination ...

Eli Lillys Mounjaro KwikPen gains approval in India, targeting diabetes and obesity with its dual-action formula for weight ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

Eli Lilly and Company (NYSE: LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...